Public Service Announcement: Phase 2 clinical trial for Oxeia’s concussion drug, OXE103

Dec 1

Written By Lindsey McClelland

Lindsey McClelland

The Defense Post: Veterans Have More to Fear from Mild Traumatic Brain Injuries than Expected

Oxeia CEO Michael Wyand participated in OneNucleus BioWednesday Webinar: Prevention vs. Cure